TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Vitrolife AB ( (SE:VITR) ) just unveiled an update.
Vitrolife AB reported a flat growth in local currencies for the second quarter of 2025, with a notable impact from currency fluctuations leading to a 7% decrease in sales in SEK. The company saw a strong performance in its Consumables segment with a 9% growth, while Technologies and Genetics saw declines. Despite the challenging currency environment, Vitrolife acquired a leading stake in AutoIVF and secured a EUR 300 million loan to refinance existing debt and support corporate purposes, indicating strategic moves to strengthen its market position.
More about Vitrolife AB
Vitrolife AB is a company operating in the healthcare sector, primarily focusing on the development and production of medical products and services for assisted reproduction. The company is listed on NASDAQ Stockholm and has a significant presence in various global markets.
Average Trading Volume: 167,594
Current Market Cap: SEK20.07B
For a thorough assessment of VITR stock, go to TipRanks’ Stock Analysis page.